bcl7a Antibody

What is BCL7A and why is it significant in research?

BCL7A (B-cell CLL/lymphoma 7 protein family member A) is a component of the SWI/SNF/BAF chromatin remodeling complex that plays critical roles in transcriptional regulation and cell fate determination. The protein was initially identified from a chromosomal translocation in a Burkitt lymphoma cell line . BCL7A is particularly significant in neurodevelopmental research as it modulates neural progenitor cell (NPC) commitment and differentiation by regulating Notch/Wnt pathway signaling and mitochondrial bioenergetics . Additionally, BCL7A influences BRG1 (the ATPase subunit of SWI/SNF) binding to chromatin genome-wide, making it a crucial factor in understanding chromatin-dependent gene regulation .

While the predicted molecular weight of BCL7A is approximately 22 kDa based on amino acid sequence , Western blot detection frequently shows bands at 55 kDa . This discrepancy is important for researchers to note when interpreting Western blot results. The higher apparent molecular weight may be due to post-translational modifications, protein-protein interactions, or particular isoforms. For accurate identification, positive and negative controls (including BCL7A knockout samples if available) should be included in experimental designs .

What are the recommended procedures for optimizing BCL7A antibody use in Western blotting?

For optimal Western blot detection of BCL7A:

• Sample preparation: Utilize cell lysis buffers containing protease inhibitors to prevent degradation of BCL7A protein.

• Protein loading: Load 10-30 μg of total protein per lane for cell lysates .

• Separation: Use 15% SDS-PAGE for optimal resolution of BCL7A .

• Transfer: Standard PVDF or nitrocellulose membranes are suitable.

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Dilute BCL7A antibody 1:500-1:1000 in blocking buffer and incubate overnight at 4°C .

• Secondary antibody: Anti-rabbit or anti-mouse HRP-conjugated antibody at manufacturer-recommended dilutions.

• Detection: Standard ECL detection systems are appropriate for visualizing the signal.

For difficult samples, consider nuclear extraction protocols as BCL7A is predominantly nuclear .

How should immunoprecipitation experiments with BCL7A antibodies be designed?

For effective BCL7A immunoprecipitation:

• Sample preparation: Use 0.35-0.5 mg of whole cell or nuclear lysate per IP reaction .

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody amount: Use 2-5 μg of BCL7A antibody per IP reaction .

• Incubation: Incubate antibody with lysate overnight at 4°C with gentle rotation.

• Bead capture: Add protein A/G beads and incubate for 1-4 hours at 4°C.

• Washing: Perform at least 3-5 washes with IP buffer containing 150-300 mM NaCl.

• Elution: Elute with SDS sample buffer at 95°C for 5 minutes.

• Controls: Include IgG control and input samples for comparison .

This approach has been validated for detecting BCL7A interactions with other SWI/SNF complex components such as BRG1 and BAF170 .

What protocols are recommended for immunohistochemical detection of BCL7A in tissue sections?

For IHC detection of BCL7A in FFPE tissues:

• Deparaffinization: Standard xylene and ethanol series.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Peroxidase blocking: 3% hydrogen peroxide for 10 minutes.

• Protein blocking: 5-10% normal serum or commercial blocking solution for 30-60 minutes.

• Primary antibody: Apply BCL7A antibody at 1:100 dilution and incubate overnight at 4°C .

• Detection system: Use polymer-HRP detection systems for optimal sensitivity.

• Counterstain: Hematoxylin for nuclear visualization.

• Automation: Automated systems like Bond (Leica) have been successfully used for BCL7A staining .

For co-localization studies, double labeling protocols can be employed to examine BCL7A expression in specific cell types, as demonstrated in studies of lymphoid tissues .

How can ChIP-seq experiments be designed to study BCL7A's influence on SWI/SNF complex genomic occupancy?

To study BCL7A's effect on SWI/SNF complex genomic localization:

• Experimental design:

  • Compare BRG1 (SMARCA4) ChIP-seq in wild-type versus BCL7A knockout cells .

  • Include H3K27me3 ChIP-seq to assess Polycomb Repressive Complex antagonism .

  • Consider parallel RNA-seq to correlate binding changes with transcriptional outcomes.

• Cell preparation:

  • Generate BCL7A knockout cells using CRISPR/Cas9 (validated in iPSCs and NPCs) .

  • Confirm BCL7A loss by Western blot and maintain SWI/SNF complex integrity verification.

• ChIP protocol:

  • Use validated BRG1 antibodies for immunoprecipitation.

  • Include input controls and non-specific IgG controls.

  • Aim for 20,000-30,000 peaks in wild-type conditions .

• Bioinformatic analysis:

  • Focus on differential binding at transcriptional start sites (TSS ± 1 kb) and enhancers (H3K4me1-enriched regions).

  • Cluster binding patterns to identify genes with decreased, increased, or unchanged BRG1 occupancy.

  • Perform motif analysis to identify affected transcription factor binding sites.

This approach revealed that BCL7A enables genome-wide BRG1 occupancy in both mouse eNPCs and human smNPCs, demonstrating its role in chromatin remodeling .

What approaches can be used to study BCL7A's role in neural progenitor cell differentiation?

To investigate BCL7A's function in NPC differentiation:

• Genetic approaches:

  • Generate conditional BCL7A knockout mice using Cre-loxP system for neuron-specific deletion .

  • Create BCL7A-deficient human iPSCs using CRISPR/Cas9 for in vitro differentiation studies .

• Differentiation protocols:

  • Use established protocols to differentiate control and BCL7A-deficient iPSCs into neural progenitor cells.

  • Monitor neuronal versus glial differentiation using immunofluorescence for specific markers (NeuN for neurons, GFAP for glia) .

• Mechanistic studies:

  • Assess Notch and Wnt signaling pathway components by immunoblotting and qRT-PCR.

  • Measure mitochondrial respiration using Seahorse XF analysis.

  • Test rescue of phenotypes with pharmacological agents (e.g., pioglitazone to enhance mitochondrial biogenesis) .

• Morphological analysis:

  • Examine dendritic branching of neurons (particularly Purkinje cells) using Golgi staining or fluorescent labeling .

  • Quantify synaptic density and neuronal connectivity.

• Behavioral assessment:

  • Evaluate motor coordination and cognitive flexibility in neuron-specific BCL7A knockout mice .

These approaches collectively revealed that BCL7A regulates NPC fate by modulating Notch/Wnt signaling and mitochondrial function, with consequences for neuronal morphogenesis and cognitive performance .

How can researchers distinguish between redundant and specific functions of BCL7 family members?

To differentiate between BCL7A, BCL7B, and BCL7C functions:

• Comprehensive knockout strategies:

  • Generate single and double knockout models (as demonstrated with BCL7A and BCL7B) .

  • Create triple knockouts if viable or use inducible systems to overcome potential lethality.

• Comparative expression analysis:

  • Perform detailed tissue and cell-type specific expression profiling of all BCL7 family members.

  • Use Western blot with specific antibodies validated against knockouts to confirm protein levels.

• Domain-specific studies:

  • Focus on the conserved N-terminal domain shared by BCL7 family members .

  • Generate chimeric proteins swapping domains between family members to identify functional specificity.

• Interactome analysis:

  • Perform immunoprecipitation followed by mass spectrometry for each BCL7 protein.

  • Compare binding partners to identify shared versus unique interactions.

• Rescue experiments:

  • Test cross-complementation by expressing BCL7B or BCL7C in BCL7A knockout cells.

  • Assess phenotypic rescue to determine functional redundancy.

Recent studies demonstrate that BCL7B is dispensable for animal survival and behavioral plasticity, while BCL7A knockout results in perinatal lethality, indicating distinct biological roles despite sequence homology .

How can researchers address non-specific binding or background issues when using BCL7A antibodies?

To minimize non-specific binding and background:

• Antibody validation:

  • Verify antibody specificity using BCL7A knockout samples as negative controls .

  • Test multiple antibody clones and formats (monoclonal vs. polyclonal) .

• Western blot optimization:

  • Increase blocking time or concentration (5-10% milk/BSA).

  • Optimize primary antibody dilution (test range from 1:250 to 1:2000).

  • Increase washing duration and number of washes.

  • Use gradient or recombinant-validated antibodies for higher specificity .

• Immunohistochemistry optimization:

  • Include absorption controls with immunizing peptides.

  • Optimize antigen retrieval conditions.

  • Use blocking peptides specific to BCL7A.

  • Employ biotin-streptavidin blocking when using biotin-based detection systems.

• Background reduction in IP:

  • Pre-clear lysates thoroughly with protein A/G beads.

  • Use VeriBlot secondary antibodies to reduce interference from IP antibody heavy chains .

  • Increase salt concentration in wash buffers gradually from 150mM to 300mM NaCl.

• Cross-reactivity considerations:

  • Be aware of potential cross-reactivity with BCL7B and BCL7C due to sequence homology.

  • Confirm antibody epitope location is in a non-conserved region when specificity is crucial.

What approaches should be taken when BCL7A antibody detection yields inconsistent or contradictory results?

When facing inconsistent or contradictory BCL7A antibody results:

• Systematic validation:

  • Verify antibody lot-to-lot consistency through standardized controls.

  • Use multiple antibodies targeting different epitopes of BCL7A .

  • Include positive controls (tissues with known BCL7A expression) and negative controls (BCL7A knockout samples) .

• Sample-specific considerations:

  • BCL7A expression varies across tissues with high levels in brain and lymphoid tissues .

  • Expression changes during development with peaks between embryogenesis and first week after birth in mouse brain .

  • Different cell types show varying expression (high in neurons, low in GFAP-positive cells) .

• Technical considerations:

  • For Western blot: The reported molecular weight of BCL7A varies (predicted 22 kDa vs. detected 55 kDa) .

  • For IHC/IF: BCL7A is predominantly nuclear, so nuclear extraction or proper permeabilization is essential .

  • For ChIP: Differential salt extraction shows BCL7A affects chromatin binding affinity of SWI/SNF complexes .

• Experimental design controls:

  • Include complementary approaches (e.g., RNA quantification alongside protein detection).

  • Consider post-translational modifications that might affect antibody recognition.

  • Account for potential isoforms (multiple transcript variants are known for BCL7A) .

When properly controlled, BCL7A antibodies have successfully revealed tissue-specific expression patterns and functional insights across multiple experimental systems .

How can BCL7A antibodies be utilized to study its role in neurological disorders and cognitive function?

BCL7A antibodies can be leveraged to investigate neurological disorders through:

• Expression profiling in patient samples:

  • Compare BCL7A levels in post-mortem brain tissues from neurological disorder patients versus controls.

  • Analyze subcellular localization changes using immunofluorescence in patient-derived iPSCs differentiated to neurons.

• Developmental studies:

  • Track BCL7A expression during critical neurodevelopmental windows using validated antibodies .

  • Correlate expression with neuronal maturation markers in normal and pathological conditions.

• Molecular mechanism investigations:

  • Use BCL7A antibodies for ChIP-seq to identify dysregulated target genes in neurological disorders.

  • Perform co-immunoprecipitation to identify altered protein interactions in disease models.

• Circuit-specific analyses:

  • Apply immunohistochemistry to study BCL7A expression in specific brain regions associated with cognitive function.

  • Combine with electrophysiological recordings to correlate expression with neuronal activity.

• Therapeutic approach validation:

  • Use antibodies to monitor BCL7A levels following treatment with potential therapeutics targeting chromatin remodeling.

  • Assess restoration of downstream pathways (Notch/Wnt signaling, mitochondrial function) in treated models .

Research has demonstrated that conditional BCL7A knockout in postmitotic neurons leads to motor abnormalities, altered Purkinje cell dendritic branching, and impacts cognitive performance, suggesting BCL7A's relevance to neurological disorders involving motor coordination and cognitive flexibility .

What are the latest advances in studying BCL7A's role in lymphoma and cancer research using antibody-based techniques?

Recent antibody-based approaches to study BCL7A in cancer include:

• Diagnostic and prognostic applications:

  • Immunohistochemical analysis of BCL7A expression in lymphoma subtypes has revealed expression in the majority of precursor and mature B cell lymphomas .

  • Expression patterns distinguish different lymphoma subtypes and correlate with clinical outcomes.

• Mechanistic investigations:

  • ChIP-seq combined with RNA-seq has revealed BCL7A's role in regulating genes implicated in tumorigenesis.

  • Co-immunoprecipitation studies have identified cancer-relevant interaction partners within the SWI/SNF complex.

• Functional genomics approaches:

  • BCL7A antibodies have been used to validate CRISPR/Cas9 knockout models in cancer cell lines.

  • Phospho-specific antibodies can detect post-translational modifications relevant to cancer signaling.

• Translational research:

  • BCL7A antibodies have helped establish connections between BCL7A and other cancer-associated genes, including MYC and immunoglobulin heavy chain (IgH) in Burkitt lymphoma .

  • Expression studies have linked BCL7A to the germinal center phenotype in diffuse large B cell lymphoma .

• Therapeutic target validation:

  • Antibody-based assays help monitor BCL7A levels following treatment with epigenetic modulators targeting SWI/SNF function.

  • Proximity ligation assays using BCL7A antibodies can detect altered protein-protein interactions following treatment.

The significance of BCL7A in cancer research originated from its identification in a three-way gene translocation with MYC and IgH in Burkitt lymphoma, where disruption of its N-terminal region is thought to contribute to lymphoma pathogenesis .

What emerging technologies are being combined with BCL7A antibodies for advanced chromatin remodeling research?

Cutting-edge approaches combining BCL7A antibodies with emerging technologies include:

• Single-cell applications:

  • Single-cell ChIP-seq using BCL7A and BRG1 antibodies to examine cell-to-cell variability in chromatin remodeling.

  • Single-cell CUT&RUN or CUT&Tag with BCL7A antibodies for higher resolution mapping of chromatin occupancy.

• Proximity-based methods:

  • BioID or APEX2 proximity labeling fused to BCL7A to identify transient interactions and local protein environments.

  • Hi-C combined with BCL7A ChIP to examine three-dimensional chromatin organization influenced by BCL7A-containing complexes.

• Live-cell imaging:

  • Development of BCL7A-specific nanobodies for live-cell imaging of chromatin remodeling dynamics.

  • FRAP (Fluorescence Recovery After Photobleaching) with fluorescently tagged antibody fragments to study BCL7A mobility.

• Multi-omics integration:

  • Integration of BCL7A ChIP-seq with ATAC-seq and RNA-seq to comprehensively map chromatin accessibility changes.

  • Combining BCL7A antibody-based proteomics with transcriptomics and metabolomics to study its role in metabolic regulation.

• Structural studies:

  • Cryo-EM studies of SWI/SNF complexes immunoprecipitated with BCL7A antibodies to determine structural roles.

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) of antibody-purified complexes to examine conformational dynamics.